Both genome-wide genetic and epigenetic alterations are fundamentally important for the
development of cancers, but the interdependence of these aberrations is poorly understood …

Monoallelic point mutations of the NADP+-dependent isocitrate dehydrogenases IDH1 and
IDH2 occur frequently in gliomas, acute myeloid leukemias, and chondromas, and display …

We have profiled promoter DNA methylation alterations in 272 glioblastoma tumors in the
context of The Cancer Genome Atlas (TCGA). We found that a distinct subset of samples …

Mutations in isocitrate dehydrogenases 1 and 2 (IDHmut) are present in a variety of cancers,
including glioma, acute myeloid leukemia (AML), melanoma, and cholangiocarcinoma …

Glioma diagnosis is based on histomorphology and grading; however, such classification
does not have predictive clinical outcome after glioblastomas have developed. To date, no …

Gain-of-function IDH mutations are initiating events that define major clinical and prognostic
classes of gliomas,. Mutant IDH protein produces a new onco-metabolite, 2 …

Extensive genomic and gene expression studies have been performed in gliomas, but the
epigenetic alterations that characterize different subtypes of gliomas remain largely …

Glioblastoma (GBM) is the most common and malignant type of primary brain tumor in adults
and prognosis of most GBM patients is poor. However, a small percentage of patients show …

Mutation in the IDH1 or IDH2 genes occurs frequently in gliomas and other human
malignancies. In intermediate grade gliomas, IDH1 mutation is found in over 70% of tumors …

IDH1 mutation is the earliest genetic alteration in low-grade gliomas (LGGs), but its role in
tumor recurrence is unclear. Mutant IDH1 drives overproduction of the oncometabolite d-2 …